Autolus Therapeutics plc

Autolus Therapeutics plc announced its participation in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference. Dr. Christian Itin, CEO, will present in a Fireside Chat on June 30, 2026. A webcast of the presentation will be available on the company's investor relations website, with a replay archived for 90 days.

Autolus Therapeutics plc announced it has been honored with the 2026 Prix Galien UK Award for Best Biotechnology Product by the Galien Foundation. This prestigious award, often likened to the Nobel Prize in biopharmaceutical research, recognizes excellence in scientific innovation to improve human health. Dr. Martin Pule, Founder and Chief Scientific Officer, highlighted the award as a testament to the company's dedication to translating pioneering research into new treatment options for patients.

Autolus Therapeutics plc announced that its Chief Executive Officer, Dr. Christian Itin, will present and host meetings at two upcoming investor conferences. He will speak at William Blair's 46th Annual Growth Stock Conference on June 2, 2026, in Chicago, and at the Jefferies Global Healthcare Conference on June 3, 2026, in New York. Webcasts and replays of both presentations will be accessible via the company's investor relations website.

Autolus Therapeutics announced the online publication of an abstract for the American Society of Clinical Oncology (ASCO) Annual Meeting, detailing positive data for its programmed T cell therapy, obe-cel. A post-hoc analysis of the Phase Ib/II FELIX study showed that obe-cel demonstrated an overall response rate of 59% and a median duration of response of 42.6 months in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) and extramedullary disease (EMD). These findings suggest obe-cel as a potential treatment option for this difficult-to-treat patient population.

Autolus Therapeutics reported a significant increase in product revenue for the first quarter of 2026, reaching $26.2 million, primarily driven by the commercialization of AUCATZYL in the US and its recent launch in the UK. Despite the revenue growth, the company's net loss slightly widened to $(71.6) million. Autolus, a foreign private issuer, voluntarily filed this 10-Q and stated that its existing financial resources are sufficient to fund operations for at least one year, even with recurring losses and an accumulated deficit of $1.46 billion.

Autolus Therapeutics reported Q1 2026 net product revenue of $26.2 million, a significant increase from $9.0 million in the prior year, driven by strong launches of AUCATZYL in the US and UK. The company achieved a positive gross margin for its ALL business for the first time, reporting a gross profit of $1.6 million. Autolus also announced a strategic initiative to reduce operating expenses by approximately $15 million annually from 2027, including a 13% workforce reduction, while progressing its obe-cel clinical development programs in lupus nephritis, pediatric ALL, and progressive MS. Despite increased revenue and positive gross margin, the net loss widened to $71.6 million, and cash reserves decreased to $229.4 million, providing a cash runway into Q4 2027.

Autolus Therapeutics plc announced it will release its first quarter 2026 financial results and operational highlights before the open of U.S. markets on Thursday, May 14, 2026. Following the release, management will host a conference call and webcast at 8:30am EDT / 1:30pm BST to discuss the results and provide a general business update.

Autolus Therapeutics plc announced a strategic initiative to improve operational efficiency and reduce operating expenses, including a workforce reduction of approximately 13%. The company expects to incur total restructuring charges of approximately $8 million, primarily for severance and related costs, with the majority recognized in the first half of 2026. These actions are projected to reduce operating expenses by approximately $15 million on an annualized basis starting in 2027. Autolus reiterated its full-year 2026 AUCATZYL net product revenue guidance of $120 million to $135 million and confirmed its cash runway into the fourth quarter of 2027.

Autolus Therapeutics plc announced a strategic initiative to improve operational efficiency and reduce operating expenses, including a workforce reduction of approximately 13%. This is expected to result in $15 million in annualized operating expense reductions starting in 2027 and $8 million in restructuring charges. The company reiterated its full-year 2026 AUCATZYL net product revenue guidance of $120 million to $135 million, up from $74 million in 2025, and anticipates a shift to positive gross margin in 2026. Clinical development programs remain on track, and the company expects its cash runway to extend into the fourth quarter of 2027.

Autolus Therapeutics plc announced that its Compensation Committee granted a total of 126,265 equity awards to 15 new employees. These awards include 68,500 stock options and 57,765 restricted stock units (RSUs), issued under the Company's 2025 Inducement Plan to attract new talent. The stock options have an exercise price of $1.47 per share and, along with the RSUs, will vest over four years, contingent on continued employment.